A well-established approach to stimulating CD4+ T helper responses in cancer vaccines involves using xenogeneic or non-tumor-specific peptides, such as the synthetic helper peptide PADRE (derived from keyhole limpet hemocyanin [KLH]) and tetanus toxoid-derived helper peptides.29 This evidence concerns the gene CD4 and cancer.